Trinitas Global is a research and data science company dedicated to predictive biomarker analysis.  The foundational technologies and supporting research of the Trinitas Risk Assessment incorporates multiple patient biomarkers to predict the likelihood of adverse immune response for patients impacted by COVID-19, with a broader applicability to a range of autoimmune disorders.

​

Many patients faced with a severe response to a disease or virus such as COVID-19 suffer from an adverse hyperactive immune responses (also known a cytokine storm), and historically there have been few reliable methods to identify those who are most at risk.  Biomarker risk assessment toolsets and supporting solutions such as those from Trinitas Global can be used to help identify and mitigate these adverse immune responses - potentially before a patient is ever exposed or symptomatic.